Researchers at pharmaceutical giant Johnson & Johnson looked at women with COVID-borne ear, nose, and throat problems for a long time; mood, neurological, skin, gastrointestinal and rheumatological disorders; and fatigue
“Women mount faster and more robust innate and adaptive immune responses, which can protect them from initial infection and severity.
“However, this same difference may make women more vulnerable to long-term autoimmune disease.”
After the first few months of the pandemic, people who developed what is now known as long COVID were also called “long transporters.”
Many long-haul carriers complained that their GPs, employers or family members did not understand or recognize the symptoms they were struggling with, months after they had overcome the first effects of the virus.
Online support groups sprang up, where members plagued by lingering effects shared stories of brain fog, breathing problems, stomach problems, fatigue, pain, anxiety, or depression.
Assuming that more than a third of people will experience long-term COVID, and Johnson & Johnson’s analysis is accurate, 1.4 million Australians may be long-term carriers, and Australian women with long-term COVID could number close to one million.
Looking at the early onset of COVID-19, Johnson & Johnson researchers noted that patients were “much more likely” to experience mood disorders such as depression, ear, nose, and throat symptoms, musculoskeletal pain, and respiratory symptoms.
Male patients, on the other hand, were prone to kidney disorders that affected the kidneys.